中国性科学
中國性科學
중국성과학
THE CHINESE JOURNAL OF HUMAN SEXUALITY
2014年
8期
39-41
,共3页
复发性生殖器疱疹%重组人干扰素α-2b凝胶%伐昔洛韦%细胞免疫%复发
複髮性生殖器皰疹%重組人榦擾素α-2b凝膠%伐昔洛韋%細胞免疫%複髮
복발성생식기포진%중조인간우소α-2b응효%벌석락위%세포면역%복발
Recrudescent genital herpes (GH)%Recombinant human interferonα-2b Gel%Valac-iclovir%Cellular immune%Reoccurrence
目的：探讨重组人干扰素α-2 b凝胶联合伐昔洛韦对复发性生殖器疱疹（GH ）患者细胞免疫功能的影响及预防复发作用。方法：选择复发性GH患者共84例，随机分为两组（对照组与观察组）。两组患者均予以伐昔洛韦胶囊300mg，2次/d，饭前空腹口服，连用4周。观察组患者加用重组人干扰素α-2b凝胶局部涂擦，4次/d，连用10d。对照组患者除不使用重组人干扰素α-2b凝胶外余治疗同观察组。观察两组患者治疗前和治疗4周后外周血T淋巴细胞亚群的变化，并比较治疗后随访6个月及1年内的复发率。结果：治疗4周后，观察组患者外周血CD4＋水平和CD4＋/CD8＋比值较前明显上升，CD8＋水平较前明显下降（P＜0.05或P＜0.01），而对照组治疗前后比较差异不明显（P＞0.05）。治疗后随访6个月及1年，观察组的复发率分别为26.19％和47.62％，均明显低于对照组的47.62％和73.81％（χ2＝4.14和6.04，P＜0.05）。结论：重组人干扰素α-2 b凝胶联合伐昔洛韦治疗复发性GH能调节外周血T淋巴细胞亚群功能紊乱，增强其细胞免疫功能，从而能降低其复发率，具有预防复发作用。
目的：探討重組人榦擾素α-2 b凝膠聯閤伐昔洛韋對複髮性生殖器皰疹（GH ）患者細胞免疫功能的影響及預防複髮作用。方法：選擇複髮性GH患者共84例，隨機分為兩組（對照組與觀察組）。兩組患者均予以伐昔洛韋膠囊300mg，2次/d，飯前空腹口服，連用4週。觀察組患者加用重組人榦擾素α-2b凝膠跼部塗抆，4次/d，連用10d。對照組患者除不使用重組人榦擾素α-2b凝膠外餘治療同觀察組。觀察兩組患者治療前和治療4週後外週血T淋巴細胞亞群的變化，併比較治療後隨訪6箇月及1年內的複髮率。結果：治療4週後，觀察組患者外週血CD4＋水平和CD4＋/CD8＋比值較前明顯上升，CD8＋水平較前明顯下降（P＜0.05或P＜0.01），而對照組治療前後比較差異不明顯（P＞0.05）。治療後隨訪6箇月及1年，觀察組的複髮率分彆為26.19％和47.62％，均明顯低于對照組的47.62％和73.81％（χ2＝4.14和6.04，P＜0.05）。結論：重組人榦擾素α-2 b凝膠聯閤伐昔洛韋治療複髮性GH能調節外週血T淋巴細胞亞群功能紊亂，增彊其細胞免疫功能，從而能降低其複髮率，具有預防複髮作用。
목적：탐토중조인간우소α-2 b응효연합벌석락위대복발성생식기포진（GH ）환자세포면역공능적영향급예방복발작용。방법：선택복발성GH환자공84례，수궤분위량조（대조조여관찰조）。량조환자균여이벌석락위효낭300mg，2차/d，반전공복구복，련용4주。관찰조환자가용중조인간우소α-2b응효국부도찰，4차/d，련용10d。대조조환자제불사용중조인간우소α-2b응효외여치료동관찰조。관찰량조환자치료전화치료4주후외주혈T림파세포아군적변화，병비교치료후수방6개월급1년내적복발솔。결과：치료4주후，관찰조환자외주혈CD4＋수평화CD4＋/CD8＋비치교전명현상승，CD8＋수평교전명현하강（P＜0.05혹P＜0.01），이대조조치료전후비교차이불명현（P＞0.05）。치료후수방6개월급1년，관찰조적복발솔분별위26.19％화47.62％，균명현저우대조조적47.62％화73.81％（χ2＝4.14화6.04，P＜0.05）。결론：중조인간우소α-2 b응효연합벌석락위치료복발성GH능조절외주혈T림파세포아군공능문란，증강기세포면역공능，종이능강저기복발솔，구유예방복발작용。
To discuss the influence and prevention reoccurrence function of recombinant hu-man interferonα-2b Gel combined with Valaciclovir on cellular immune function of patients with recrudescent geni-tal herpes (GH).Methods:84 patients with recrudescent GH were selected and divided into control group and ob-servation group at random.The patients in two groups were given 300mg Valaciclovir capsules twice a day through the mouth with empty stomach before dinner for 4 weeks.The patients in observation group were additionally given recombinant human interferonα-2b Gel,which was greased locally four times a day for 10 days.Except for recom-binant human interferon α-2b Gel,the patients in control group were given the same medical treatment as that in observation group.The changes of peripheral blood T lymphocyte subsets of patients in two groups before and after medical treatment were observed,and reoccurrence rates of 6 months’and 1 year’s following-up was compared. Results:After 4 weeks’medical treatment,the peripheral blood CD4 +levels and CD4 +/CD8 +ratio of patients in observation group obviously higher than before,while CD8 +level obviously declined (P<0.05 and P<0.01 ), and no obvious difference appeared in control group before and after medical treatment (P>0.05).According to 6 months’and 1 year’s following -up,the reoccurrence rates of patients in observation group were 26.19% and 47.62%,which were all much lower than those in control group (47.62 %and 73.81 %)(χ2 =4.14 and 6.04, P<0.05).Conclusion:The treatment of recombinant human interferon α-2b Gel combined with valaciclovir on recrudescent GH,can adjust the functional disorder of peripheral blood T lymphocyte subsets and strengthen the cel-lular immune function,which,therefore,reduces the reoccurrence rate and can prevent reoccurrence.
